Advisory Services Network’s GT Biopharma GTBP Stock Holding History

Advisory Services Network’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,000	Closed	-$7.85K	–	4836
2025 Q4	$7.85K	Buy	+10,000	New	+$7.1K	﹤0.01%	1800
2024 Q1	–	Sell	-5	Closed	-$38	–	2362
2023 Q4	$38	Buy	+5	New	+$37	﹤0.01%	3820
2023 Q2	–	Sell	-5	Closed	-$83	–	2344
2023 Q1	$83	Hold	5	–	–	﹤0.01%	3910
2022 Q4	$143	Buy	+5	New	+$250	﹤0.01%	3888
2021 Q3	–	Sell	-5	Closed	-$2K	–	2169
2021 Q2	$2K	Buy	+5	New	+$2.08K	﹤0.01%	3316

Other funds holding GTBP

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

AAP

Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SWM

SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return

Advisory Services Network's GTBP Position: Q1 2026 in Review

Advisory Services Network sold out of GT Biopharma (GTBP) in Q1 2026, closing a stake of 10,000 shares — an estimated $7.85K sold.

Advisory Services Network first reported a position in GTBP in Q2 2021 and held it in 5 quarters. The position peaked at $7.85K in Q4 2025. 42 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

Advisory Services Network reported no remaining GT Biopharma position as of Q1 2026 after selling out during the quarter.
Advisory Services Network sold 10,000 GT Biopharma shares in Q1 2026, an estimated $7.85K.
Advisory Services Network first reported a position in GT Biopharma in Q2 2021 and held it in 5 quarters.
Advisory Services Network's GT Biopharma position peaked at $7.85K in Q4 2025.
42 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on Advisory Services Network's 13F filing for Q1 2026, filed 15 May 2026.